Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00541164|
Recruitment Status : Completed
First Posted : October 10, 2007
Last Update Posted : July 15, 2013
|Condition or disease||Intervention/treatment||Phase|
|Charcot Marie Tooth Disease||Drug: Coenzyme Q10 Dietary Supplement: Coenzyme Q10||Phase 1 Phase 2|
CoQ10 is an integral part of the electron transport chain in the mitochondria, or the energy production centers of cells. Within recent years, there has been expanding interest in the potential benefits of CoQ10 supplementation on a variety of neuromuscular diseases, some of which involve mitochondrial dysfunction, such as CMT. Daily supplementation may have cytoprotective and neuroprotective properties, which may improve symptoms of weakness, fatigue, and pain, as well as increase quality of life (QOL) among persons with CMT.
With regards to within group comparisons we hypothesize that daily supplementation of CoQ10 taken as a 300 milligram wafer twice a day for 3 months will produce a statistically significant reduction in weakness, fatigue, and pain, along with a significant improvement in QOL as indicated from scores in both standardized physiological and scale measures.
The addition of serum level analysis will help to contextualize clinical results. We hypothesize the ratios of the oxidized and reduced forms of CoQ10 will be modified upon supplementation.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Supportive Care|
|Official Title:||Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study|
|Study Start Date :||September 2007|
|Actual Primary Completion Date :||January 2013|
|Actual Study Completion Date :||January 2013|
300 mg CoQ10 chewable wafer twice a day
Drug: Coenzyme Q10
300 mg CoQ10 twice a day for 48 weeks
Placebo Comparator: 2
Chewable placebo wafer twice a day for 24 weeks with crossover to 300mg CoQ10 twice a day for weeks 24-48.
Dietary Supplement: Coenzyme Q10
300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
- Changes in weakness, fatigue and pain in persons with Charcot-Marie-Tooth disease after supplementation with 600 mgs a day of Coenzyme Q10. [ Time Frame: 60 weeks ]
- Improvements in quality of life in subjects with CMT before and after CoQ10 supplementation. [ Time Frame: 60 weeks ]
- Measure blood serum levels of the oxidized and reduced forms of CoQ10. [ Time Frame: 60 weeks ]
- Measure liver function tests [ Time Frame: visits 1, 6, 12 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00541164
|United States, Pennsylvania|
|John P Murtha Neuroscience and Pain Institute|
|Johnstown, Pennsylvania, United States, 15904|
|Principal Investigator:||Sharon Plank, MD||John P. Murtha Neuroscience and Pain Institute|